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Abstract
The mucopolysaccharidoses (MPS) are clinically similar but also heterogeneous in terms of major or minor involvement of
different organs/systems, burden of disease, and rate of progression. The attenuated forms of MPS, due to their less severe
presentations, are more difficult to diagnose and often receive a significantly delayed diagnosis. On the other hand, the
diagnosis is very important since the attenuated forms may benefit from earlier treatments. The aim of this paper is to
describe the natural history and the clinical signs useful to arise a suspicion of an attenuated form of MPS. MPS patients
usually show a cluster of signs and symptoms, one of which may be the trigger for an evaluation by a specialist.
Individuals with attenuated MPS are mostly cognitively normal, and dysmorphisms of the facies may be mild or absent.
The most frequently involved organs/systems are the osteoarticular system, heart, and eyes. These patients may also have
hepatosplenomegaly, hearing loss, and respiratory problems. When they are referred to a specialist (rheumatologist,
cardiologist, ophthalmologist, surgeon, orthopedist, etc.) for their main complaint, the other signs and symptoms are likely
to be missed in the medical history. To avoid missing data and to save time, we propose a semistructured medical history
form to be filled in by the patients or their caregivers while waiting for evaluation by a specialist.
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Background
Mucopolysaccharidoses (MPS) are genetic, multisystem, and
progressive diseases where virtually all the organs and sys-
tems are involved. Thus far, seven types of MPS are known:
type I, II, III, IV, VI, VII, and IX. These are similar, but also
have a significant inter- and intra-disease variability in their
onset, organs and systems involvement, and clinical course.
The intra-disease variability is mainly due to different
underlying mutations and the consequent degree of residual
enzyme activity [1]; usually there is a correlation between
severity of the disease and the age of its onset, with the
more severe disease having an earlier onset. The attenuated
forms of MPS are more difficult to diagnose since the dis-
ease progresses silently over decades and early symptoms
are subtle and may be overlooked by physicians who are not
familiar with the disease. The more frequent signs and
symptoms of late-onset MPS patients are related to heart
valve, joints, and eyes (Table 1) [2, 3]. A frequent picture is
that of a patient with the onset of noninflammatory joint
contractures in childhood which are initially diagnosed as
rheumatoid arthritis, juvenile idiopathic arthritis, or sclero-
derma and, after many years of misdiagnosis, these are iden-
tified as MPS signs [4]. In a number of cases, joint stiffness
is associated with a heart murmur and/or eye problems [2].
The accumulation of glycosaminoglycan (GAGs) in the ly-
sosomes is the pathogenic trigger of MPS manifestations.
Since nowadays the majority of MPS are treatable disorders
and the attenuated forms can benefit consistently from early
treatments, our efforts should focus on shortening the gap
between the onset of symptoms and the final diagnosis.
The aim of this paper is to describe the natural history
and the most common signs useful to reach the suspicion
of an attenuated form of MPS.
What is relevant for suspicion?
The presence of signs and symptoms in a cluster is very
important for a suspicion of MPS.
This paradigm might not be easily taken into account be-
cause a specialist may only look at signs within her/his spe-
cific competence, without being able to look into the other,
possibly milder, signs or symptoms that should arouse a
clinical suspicion.
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Clinical history is essential since an attenuated patient
can meet a specialist for a specific problem but, during the
medical history interview, another two or three mild signs
or symptoms may be noticed which can lead to suspicion
of MPS. The family history should also be collected since
MPS are hereditary disorders and other family members
could be affected.
With this purpose in mind, we are proposing a semistruc-
tured medical history form (see Appendix) that can be used
under different settings by rheumatologists, cardiologists,
ophthalmologists, surgeons, and other specialists, and ap-
plies to all of the patients who present one of the typical
somatic signs of MPS. This is adapted from a previous
questionnaire proposed for rheumatologists [5], and it will
be useful to raise a suspicion for all MPS types, except for
MPS type III which has mainly neurocognitive signs.
In summary, symptoms present in a cluster, and family
and individual histories are of upmost importance.
The natural history in attenuated forms of MPS
For each type of MPS two different phenotypes can be
recognized, severe and attenuated. Such a classification
is sometimes useful, although there is a phenotypic con-
tinuum among the different types.
The two main characteristics of all the attenuated types of
MPS are the later onset and the slower progression com-
pared with the severe forms. The disease onset is generally
in the pediatric age, but the signs are mild and for this rea-
son they can be overlooked and/or misdiagnosed.
The height of the adult individual is usually lower than
that of the general population, but in some cases pa-
tients may show normal growth [2, 6].
With the exception of attenuated MPS III, where the first
sign is cognitive/behavioral involvement, in the other atten-
uated forms of MPS the first signs are in general somatic
and the majority of patients show normal intellectual per-
formances with only a small number of Hurler-Scheie and
attenuated Hunter patients showing variable degrees of
learning and attention difficulties [2, 7].
For these, osteoarticular manifestations are the first or
the second sign of disease expression appearing in MPS I
Scheie (the attenuated form of MPS I) at a median age of
7.5 years in around 70% of patients [8] and this is pre-
ceded by the occurrence of umbilical/inguinal hernias at a
median age of 4.6 years [8–10]. Heart valve disease and
corneal clouding are also signs found in around 70% of
MPS I Scheie patients, appearing at the end of the first
decade of life.
Table 1 Skeletal, cardiac, and ocular features for each type of attenuated MPS as summarized from the literature +++ = most/all; +
+ = several; + = few
Clinical features MPS I MPS II MPS III MPS IV MPS VI MPS VII MPS IX References
Skeletal [2–4, 6–12, 24, 25, 28–30, 32, 33]
Short stature + ++ + +++ ++ ++ +
Gibbus deformity + ++ – – ++ ++ –
Valgus knee + ++ – +++ ++ ++ –
Pectus carinatum + + – +++ + + –
Scoliosis ++ ++ + +++ ++ + –
Hip dysplasia +++ ++ + +++ ++ +++ –
Atlanto-axial instability + – – +++ ++ + –
Cord compression ++ ++ – +++ ++ ++ –
Carpal tunnel syndrome +++ +++ – – +++ + –
Arthropathy +++ +++ + +++ +++ +++ +++
Joint stiffness +++ +++ + – +++ +++ –
Joint laxity – – – +++ – – –
Joint effusion – – – – – – +++
Heart [14, 16, 17, 19]
Valvulopathy +++ +++ + + +++ ++ UN
Hypertrophic cardiomyopathy + ++ – – + + UN
Eye [21, 22]
Corneal clouding +++ + + + +++ +++ UN
Retinal degeneration +++ ++ ++ ++ UN UN UN
Glaucoma ++ + + + ++ ++ UN
+++ most/all, ++ several, + few
MPS mucopolysaccharidoses, UN unknown
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The attenuated forms of MPS may have mild facial dys-
morphisms which begin to appear in childhood and tend to
worsen over time (Fig. 1) [8, 9]. Dysmorphisms, however,
are not the rule since in many attenuated patients they are
very mild or absent [11].
Life expectancy can be nearly normal, and some patients
may also reproduce [12, 13]. In summary, there is slow
progression, no cognitive delay, and hernias, osteoarticular
involvement, eye, and heart valve disease are the most fre-
quent signs.
Which kind of cardiac involvement is typical of MPS?
Cardiac involvement is a main sign, common to all the atten-
uated forms of MPS including MPS III, and heart malfunc-
tioning is one of the causes of major somatic complications
and death [14] (see also Boffi et al. [15] in this supplement).
Valvulopathy is the main cardiac sign in MPS individ-
uals with slowly progressing disease. The mitral and aor-
tic valves are the most commonly affected, irrespective
of the type of MPS, with valve thickening and regurgita-
tion, followed by stenosis [16, 17].
MPS I, II, and VI patients, whose GAG accumulation
consists of dermatan and heparan sulfate, have a faster pro-
gression of valvulopathy compared with MPS III and IV pa-
tients where dermatan sulfate is not stored [16, 18].
Other common features are left ventricular hypertrophy,
abnormal diastolic function, and coronary artery disease.
Pulmonary hypertension may arise as a consequence of air-
ways obstruction, deformity of the ribs, or GAG storage in
the walls of pulmonary vessels. The GAG storage also
causes an abnormal conduction of the electric signal
(arrhythmia, complete heart block) [18, 19]. Enzyme re-
placement therapy (ERT) may have a positive impact on left
ventricular hypertrophy [19, 20] while it generally does not
improve the cardiac valve disease, although it may attenuate
or delay its progression [19, 20].
Cardio-surgery is a good option to treat these complica-
tions but, as with other surgical procedures, the risk of ad-
verse events during or immediately after surgery increases
in MPS patients [17] (see Moretto et al. in this Supplement
[18]). Rehabilitation may be difficult in the presence of
orthopedic issues. In summary, valvulopathy is the most fre-
quent cardiac sign in attenuated MPS.
Which kind of ocular involvement is typical of MPS?
Corneal clouding (Fig. 2) is another typical finding of attenu-
ated MPS. It progresses over time and often requires corneal
transplantation in early adulthood [21, 22] (see also Del
Longo et al. in this Supplement [23]). This might be effective
in ameliorating the sight of MPS patients provided they are
not affected by retinopathy. Corneal clouding is frequently
severe in MPS I and VI patients, while it is less severe in
MPS IV and MPS VII and usually mild in MPS II and III. In
MPS I Scheie, the onset of corneal clouding was reported at
a median age of 10.5 years and it can be associated with
glaucoma, increased intraocular pressure, and retinal degen-
eration [8, 9, 21, 22]. Retinal degeneration is frequently seen
in adult patients affected by MPS I, II, and III, more rarely in
MPS IV patients, and it has not been reported for MPS VI
patients [6, 21–24]. Ocular manifestations in MPS IX have
not been studied [22]. In summary, corneal clouding and ret-
inal degeneration are associated with attenuated MPS.
Which kinds of osteoarticular manifestations are typical
of MPS?
The GAG deposition in the growth plate causes endochon-
dral ossification of the physis. Thus, it results in growth de-
cline and eventually in short stature [25–28]. The storage is
always evident in the cartilage, tendons, and joints. Studies
on MPS animal models have documented an abnormal
Fig. 1 Six-year-old MPS II attenuated patient with very mild facial signs
of the disease
Fig. 2 Severe corneal clouding in a 60-year-old patient affected by
MPS IVA
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composition of the cartilage matrix and apoptosis of chon-
drocytes with release of nitric oxide and elevated levels of
tumor necrosis factor (TNF)-alpha. The inflammation plays
a pivotal role inside the joints, but it is not clinically evident
[29]. Features are very similar to those of human osteoarth-
ritis, although the presence of high levels of TNF-alpha in
the synovium may also explain why the clinical picture can
mimic rheumatic inflammatory diseases [30]. Over time, pa-
tients with milder forms of MPS may develop clinical pic-
tures characterized by joint contractures with reduced range
of motion, claw hands (Fig. 3), trigger finger, carpal tunnel
syndrome (CTS), dysostosis multiplex with atlanto-axial in-
stability associated with hypoplasia of the odontoid process,
kyphoscoliosis, hip dysplasia, varus knee, pes cavus/planus,
and genu valgum. The x-ray images may also be not typical
of MPS, showing aspecific osteoarthrosis in certain cases
(Fig. 4). Patients with all MPS types (except MPS III) can
suffer from compressive myelopathy both in the
cranio-cervical and dorso-lumbar regions, with severe
neurological consequences [6, 8–11, 24, 31, 32].
Spinal canal stenosis is caused by thickening of the soft
elements (dura, ligamentum flavum, cruciate ligaments),
disc bulging, spinal deformities, or a combination of these
factors [33].
MPS IVA can usually be clinically distinguished from
other MPS by the presence of additional skeletal manifesta-
tions derived from a unique epiphyseal chondrodysplasia
and laxity of joints [6, 32].
Stiffness and contractures usually start in childhood;
they are not associated with swelling, warmth, or tender-
ness, and are especially localized at the hands (Fig. 3). The
pathological accumulation in the tendons may involve in-
terphalangeal joints and causes important impairment to
hand function (claw hands). These aspects can also mimic
camptodactyly or diabetic cheiroarthropathy.
For all the above reported presenting signs, patients
will come to the attention of the rheumatologists and/or
orthopedic surgeons or neurosurgeons.
The medical literature contains individual case reports or
small cohorts of attenuated MPS patients with onset of
symptoms in childhood who were finally identified after
many years and sometimes decades, with a range up to
50 years. In some of these patients, misdiagnoses of
rheumatoid arthritis, juvenile idiopathic arthritis, or sclero-
derma had been maintained for several years [8, 10, 34].
In the very few reports on MPS IX, patients are de-
scribed with periarticular nodular soft tissue masses with
short stature, episodes of painful joint swelling, no joint
stiffness and no kypho-scoliosis [35].
Another important orthopedic aspect is the occurrence
of carpal tunnel syndrome (CTS) in children or adoles-
cents, which is otherwise rare in the pediatric age. Thus, a
history of juvenile carpal tunnel release surgery must raise
the suspicion of a metabolic or genetic disorder and espe-
cially of MPS (I, II, and VI) which accounts for more than
half of the cases in this age group [8]. In MPS, clinical
signs typical of adult CTS such as nocturnal paresthesia
may be absent; the most frequent finding is a difficulty
with fine motor tasks [33]. In summary, joint contractures
without inflammatory signs, carpal tunnel syndrome, and
radiological signs of (attenuated) dysostosis multiplex are
particularly suggestive of MPS.
Are other organs involved, and how?
All MPS types show recurrent infections of the upper re-
spiratory tract, such as recurrent rhino- and oto-sinusitis
(especially in the first decade of life), restrictive lung disease,
and obstructive sleep disturbances/snoring [32, 36, 37].
The attenuated forms may present with airway ob-
structions from the rhino-pharynx to the peripheral
bronchi. The submucosal storage material is often
the cause of the upper airway obstruction.
A complication, particularly frequent and often lethal in
MPS II and IV, is tracheal stenosis caused by tracheomalacia
Fig. 3 Claw hands of an adult patient affected with attenuated MPS II
Fig. 4 Bilateral coxarthrosis with reduction of the acetabular spaces
in a patient affected by MPS I Scheie
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and often associated with external compression. Usually,
these stenoses arise in the teenage years and are progressive;
thus far, no conclusive guidelines have been set regarding
their management and treatment, although surgical treat-
ment have been successful in some patients [38, 39].
Hypoacusia is frequent and may be due to conductive or
sensorineural hearing loss, or both. Hearing loss may develop
in attenuated MPS, most commonly in the high frequency
range, and probably due to accumulation of GAGs both in
the ossicles of the middle ear and in the acoustic nerve [40].
Gastrointestinal involvement is also described as hepa-
tosplenomegaly or diarrhea to a variable degree and per-
centage. Hernias (inguinal, umbilical) are present in
approximately 65% of MPS I Scheie and they are often the
onset sign [41]. In summary, sleep disturbances, tracheo-
malacia and/or stenosis, hypoacusia hernias, and mild
hepatosplenomegaly are often associated with the clinical
picture of attenuated MPS.
Is apparently isolated cognitive insufficiency a sign of
MPS; the MPS III attenuated phenotype
MPS III differs from the other types of MPS in that
it is mainly a neurodegenerative disorder with a
milder somatic involvement. MPS III is characterized,
after an initial symptom-free interval, by behavioral
problems followed by progressive mental deterioration
leading to severe dementia [42]. If one considers the
spectrum of the classic phenotypes, subtype A is in
general more severe and has an earlier age of death
than the other subtypes [43–45].
As for the other types of MPS, MPS III patients can
also be divided into two phenotypic groups, rapidly
progressing and slowly progressing, according to the
progression of their clinical course [46]. Among the
slowly progressing, there are patients who can reach re-
markably advanced ages with a clinical picture charac-
terized by unexplained mental retardation/insufficiency
associated with behavioral problems such as restless-
ness, screaming, hypersensitivity to touch, anxiety, ag-
gression, and sleep disturbances, including frequent
awaking. The neurological degeneration arises in the
fourth to sixth decades with loss of motor function, loss
of speech, epilepsy, loss of sphincter control and, in the
end, swallowing problems [47].
In this attenuated MPS III phenotype, the somatic in-
volvement could be very mild and present only in ad-
vanced age. The most frequent physical problems consist
of cardiac disease (cardiomyopathy, arrythmias), arthritis,
skin blistering, hernias, and susceptibility to infections.
For all these reasons, unexplained mental retardation
and behavioral problems in adults should prompt meta-
bolic investigation for MPS III [47, 48]. In summary, MPS
III must be suspected in patients with unexplained cogni-
tive delay mainly if associated with behavioral problems.
What are the red flags that should prompt the diagnosis
of an MPS?
A group of rheumatologists and pediatricians together
with MPS experts have developed a diagnostic algorithm
based on rheumatologic aspects of MPS [34].
The suspicion of MPS should arise when a patient shows
important joint contractures (not associated with either
swelling or local inflammation) or stiffness. Moreover, in-
flammatory markers are absent, there is no response to ste-
roids or nonsteroidal anti-inflammatory drugs, and no
radiological evidence of erosive aspects. Urinary GAG might
be absent in adult patients with attenuated forms of MPS.
For this reason, the diagnosis should not be excluded if
the first quantitative GAG dosage is negative. All the
symptoms of the patients should be re-evaluated (Table 2)
and other tests (qualitative urinary GAG, enzyme, and
molecular analysis), (see Filocamo et al. in this Supple-
ment [49]) performed in case the suspicion is confirmed.
A semistructured form to be self-completed by the pa-
tients or their caregivers while waiting for the evaluation of
a specialist (mainly cardiologists, rheumatologists, orthope-
dists, and ophthalmologists) is reported in Appendix. It has
been retrospectively tested on 16 clinical records of attenu-
ated MPS; if this questionnaire had been used, all the pa-
tients could have been diagnosed earlier. The advantage of
this semistructured history is that the physician has a se-
lective medical history already available at hand for exclud-
ing or suspecting an MPS or other rare genetic diseases
involving the bones.
Conclusions
The attenuated forms of mucopolysaccharidoses represent
a continuum from the most severely affected patients
showing different degrees of severity. They may remain
apparently asymptomatic for years with a silently progres-
sing disease and only be recognized at an advanced dis-
ease stage when it is too late for any intervention.
Awareness among medical specialists in adult medicine
should be raised so that they can play an important role not
only in the management but also in the diagnosis of MPS.
Table 2 “Red flags” signs for early diagnosis of attenuated
mucopolysaccharidoses
“Red flag” sign
Noninflammatory joint stiffness +++
Juvenile Carpal tunnel syndrome +++
Heart valve disease +++
Corneal clouding +++
Skeletal abnormalities ++
Hernias ++
Hepatomegaly +
Produced from data in [2–4, 6–12, 14, 16, 17, 19, 21, 22, 24, 28–30, 32, 33]
+++ very suggestive, ++ suggestive, + faintly suggestive
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A precise and sophisticated diagnosis of a particular
type of MPS is not expected only on clinical grounds
since there is a significant overlap between the various
types. It will be enough for the specialist to suspect that
the patient may suffer from MPS.
In this respect, signs such as umbilical and/or in-
guinal hernia, juvenile CTS, bone deformities and joint
contractures without apparent inflammation, heart
valve disease, or eye problems should be regarded as
red flags useful to raise a clinical suspicion (Table 2).
An accurate medical history is essential to identify all
these signs. Our tool for a semistructured medical his-
tory will help to refer the patient to the appropriate
physician (MPS expert) to avoid a medical odyssey and
start the appropriate treatment as soon as possible.
MPS are treatable disorders, and their diagnosis has
implications for the patient’s quality of life and life
expectancy.
Appendix
Table 3 Semi-structured history form to be completed by the patient while waiting for the specialist evaluation (cardiologist,
rheumatologist, orthopedist, ophthalmologist)
Questions Answers I don’t understand Observations
Yes No I don’t know
Eye involvement
Have you ever had ocular
problems?
If yes Has an eye care specialist ever said that you suffer from:
• corneal opacities
• retinal pigmentation
• retinal degeneration
• glaucoma
• atrophy of the optic nerve
Heart involvement
Have you ever had heart
problems?
If yes Has a cardiologist ever told you that you have heart valve
abnormalities?
Ear, nose and throat involvement
Have you ever had hearing
and /or respiratory
problems?
If yes Have you ever had:
• permanent rhinitis
• repeated infections of the upper airways
• hearing loss
• language delay
• laryngotracheal stenosis
• tonsillectomy
• adenoidectomy
• wheezing with your shortness of breath
• sleep apnea
Musculoskeletal involvement
Have you ever had
musculoskeletal problems?
If yes Have you ever had:
• spinal cord compression (a severe thickening of the
tissue along the spine)
• contractures or joint deformity
• skeletal deformity not secondary to trauma
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Abbreviations
CTS: Carpal tunnel syndrome; ERT: Enzyme replacement therapy;
GAG: Glycosaminoglycan; MPS: Mucopolysaccharidosi(e)s; TNF: Tumor
necrosis factor
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